Fig. 5: Progression-free survival of anal cancer patients according to p16ink4a/p53 status.

All patients were subdivided into three groups (p16ink4a-positive/p53 non aberrant vs. p16ink4a-positive/p53 aberrant vs. p16ink4a-negative). The intermediate prognosis of HPV-driven neoplasms displaying a mutated TP53 should be noticed.